Markers of endothelial activation and atherothrombosis in women with history of preeclampsia or gestational hypertension

Summary

Women who have had preeclampsia (PE) or gestational hypertension (GH) exhibit relatively high rates of circulatory diseases. PE is a disease associated with inflammation and vascular endothelial dysfunction. We therefore hypothesised that women with a history of PE or GH might have abnormal levels of markers of endothelial activation or inflammation, reflecting either an innate predisposition to preeclampsia or changes induced by the eclamptic process. Levels of von Willebrand factor, fibrinogen and C-reactive protein were compared in 392 women with a history of PE between 1951 and 1970, 297 women with a history of GH and 163 matched controls. Although no significant differences between those with either PE or GH and controls were noted, subjects with a history of PE had significantly higher CRP values than those with GH. No significant differences were found when the three groups were compared for von Willebrand factor or fibrinogen. Overall, the data do not support our hypothesis.

In addition, our data document increasing von Willebrand factor levels increase with age, which may help explain the age dependent increase in venous or arterial thrombosis. Moderate alcohol consumption was also associated with lower levels of inflammatory markers.

Keywords

Preeclampsia - fibrinogen - von Willebrand factor - C-reactive protein - vascular endothelium

• References

• 1 Roberts JM, Cooper DW. Pathogenesis and genetics of preeclampsia. Lancet 2001; 357: 53-6.
• 2 Esplin MS, Fausett MB, Fraser A. et al. Paternal and maternal components of the predisposition to preeclampsia. NEJM 2001; 344: 867-72.
• 3 Higgins JR, de Swiet M. Blood pressure measurement and classification in pregnancy. Lancet 2001; 357: 131-5.
• 4 Brosens IA, Robertson WB, Dixon HG. The role of the spiral arteries in the pathogenesis of preeclampsia. In: Wynn R, ed. Obstetrics and Gynecology Annual 1979; 177-191.
• 5 Pijnenborg R. et al. Placental bed spiral arteries in the hypertensive disorders of pregnancy. Br J Obstet Gynae 1991; 986: 48-55.
• 6 Taylor RN. et al. Selective effects of preeclamptic sera as human endothelial cell pro-coagulant protein expression. Am J Obst Gynecol 1991; 165: 1705-10.
• 7 Roberts JM. Endothelial dysfunction in preclampsia. Semin Reprod Endocrinol 1998; 16: 5-15.
• 8 Verhaar MC, Rabelink TJ. The endothelium: a gynecological and obstetric point of view. Eur J Obst Gyn & Reprod Biol 2001; 94: 180-5.
• 9 Roberts JM, Taylor RN, Musci TJ. et al. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989; 161: 1200-4.
• 10 Krauss T. et al. Circulating endothelial cell adhesion molecules as diagnostic markers for the early identification of pregnant women at risk for development of preeclampsia. Am J Obst Gynecol 1997; 177: 443-9.
• 11 Sibai BM. Risk factors, pregnancy complications, and prevention of hypertensive disorders in women with pregravid diabetes mellitus. J Matern-Fetal Med 2000; 9: 62-5.
• 12 Sugi T, Makino T. Autoantibodies to contact proteins in patients with recurrent pregnancy losses. J Reprod Immunol 2002; 53: 269-77.
• 13 Greaves M. Antiphospholipid antibodies and thrombosis. Lancet 1999; 353: 1348-53.
• 14 Chesley LC. et al. The familial factor in toxemia of pregnancy. Obst Gynecol 1968; 32: 303-11.
• 15 Lachmeijer AM, Aarnoudse JE, ten Kate LP. et al. Concordance for pre-eclampsia in mono-zygous twins. Br J Obstet Gynecol 1998; 105: 1315-7.
• 16 Thornton JG, Macdonald AM. Twin mothers, pregnancy hypertension and pre-eclampsia. Br J Obstet Gynaecol 1999; 106: 570-5.
• 17 Ros HS, Lichtenstein P, Lipworth L. et al. Genetic effects on the liability of developing pre-eclampsia and gestational hypertension. Am J Med Genet 2000; 91: 256-60.
• 18 Chesley LC, Annitto JE, Cosgrove RA. The remote prognosis of eclamptic women. Sixth periodic report. Am J Obstet Gynecol 1976; 124: 446-59.
• 19 Fisher KA, Luger A, Spargo BH. et al. Hypertension in pregnancy: clinical-pathological correlations and remote prognosis. Medicine 1981; 60: 267-76.
• 20 Jonsdottir LS, Arngrimsson R, Geirsson RT. et al. Death rates from ischemic heart disease in women with a history of hypertension in pregnancy. Acta Obstet Gynecol Scand 1995; 74: 772-6.
• 21 Wilson BJ, Watson SM, Prescott GJ. et al. Hypertensive diseases of pregnancy and the risk of hypertension and stroke in later life. Br Med J 2003; 326: 845-9.
• 22 Fujimura Y, Titani K. ‘Structure and Func-tion of von Willebrand factor&rsquo. In Bloom AL, Forbes CD, Thomas DP. EGD Tuddenham -Haemostasis and Thrombosis, 3^rd ed Edinburgh, UK: Chur-chill Livingstone; 379-96.
• 23 Mannucci PM. Von Willebrand factor: a marker of endothelial damage?. Arterioscler, Thromb Vasc Biol 1998; 18: 1359-62.
• 24 Whincup PH, Danesh J, Walker M. et al. Von Willbebrand factor and coronary heart disease Prospective study and meta-analysis. Eur Heart J 2002; 23: 1764-70.
• 25 Kumari M, Marmot M, Brunner E. Social determinants of von Willebrand factor: the Whitehall II study. Arterioscler Thromb Vasc Biol 2000; 20: 1842-7.
• 26 Szalai AJ, van Ginkel FW, Dalrymple SA. et al. Testosterone and IL-6 requirements for human C-reactive protein gene expression in transgenic mice. J Immunol 1998; 160: 5294-5299.
• 27 Weinhold B, Bader A, Poli V. et al. Interleukin-6 is necessary, but not sufficient, for induction of the human C-reactive protein gene in vivo. Biochem J 1997; 325: 617-21.
• 28 Culley FJ, Bodman-Smith KB, Ferguson MA. et al. C-reactive protein binds to phosphory-lated carbohydrates. Glycobiology 2000; 10: 59-65.
• 29 Danesh J, Collins R, Appleby P. et al. Association of fibrinogen, C-reactive protein, albumin or leukocyte count with coronary heart disease: meta-analysis of prospective studies. JAMA 1998; 279: 1477-82.
• 30 Danesh J, Whincup P, Walker M. et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000; 321: 199-204.
• 31 Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-8.
• 32 Redman CW, Sacks GP, Sargent IL. Preeclampsia, an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999; 180: 499-506.
• 33 Ray A. A SAF binding site in the promoter region of human gamma-fibrinogen gene functions as an Il-6 response element. J Immunol 2000; 165: 3411-17.
• 34 Hutchinson WL. et al. Immunoradiometric assay of circulating C-reactive proteins: age-related values in the adult general population. Clin Chem 2000; 46: 934-68.
• 35 Thun MJ, Peto R, Lopez AD. et al. Alcohol consumption and mortality among middle aged and elderly US adults. NEJM 1997; 337: 1705-14.
• 36 Clausen T, Djurovic S, Brosstad FR. et al. Altered circulating levels of adhesion molecules at 18 weeks’ gestation among women with eventual preeclampsia: indicators of disturbed placentation in absence of evidence of endothelial dysfunction?. Am J Obstet Gynecol 2000; 182: 321-5.
• 37 Chambers JC, Fusi L, Malik IS. et al. Association of maternal endothelial dysfunction with preeclampsia. JAMA 2001; 285: 1607-12.
• 38 Mayosi BM, Vickers MA, Green FR. et al. Evidence of a quantitative trait locus for plasma fibrinogen from a family-based association study. Genescreen 2001; 1: 151-5.
• 39 Vickers MA. et al. Genotype at a promoter polymorphism of the interleukin-6 gene is associated with plasma C-reactive protein. Cardiovasc Res 2002; 53: 1029-34.
• 40 Ross R. Atherosclerosis – an inflammatory disease. NEJM 1999; 340: 115-26.
• 41 Grandone E. et al. Prothrombotic genetic risk factors and the occurrence of gestational hypertension with or without proteinuria. Thromb Haemost 1999; 81: 349-52.
• 42 Morrison ER, Miedzybrodzka ZH, Campbell DM. et al. Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb Haemost 2002; 87: 779-85.
• 43 Kraaijenhagen RA. et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000; 83: 5-9.
• 44 Kyrle PA, Minar E, Hirschl M. et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. NEJM 2000 343: 457-62.
• 45 Kamphuisen PW, Lensen R, Houwing-Duistermaat JJ. et al. Heritability of elevated factor VIII antigen levels in factor V Leiden families with thrombophilia. Br J Haem 2000; 109: 519-22.
• 46 Kamphuisen PW, Rosendaal FR, Eikenboom JC. et al. Factor V antigen levels and venous thromobosis: risk profile, interaction with factor V Leiden and relation with factor VIII antigen levels. Arterioscler, Thromb Vasc Biol 2000; 20: 1382-6.
• 47 Imhof A, Froehlich M, Brenner H. et al. Effect of alcohol consumption on systemic markers of inflammation. Lancet 2001; 357: 763-7.